Novel Treatment Concepts in Psoriatic Arthritis

Rheum Dis Clin North Am. 2015 Nov;41(4):739-54. doi: 10.1016/j.rdc.2015.07.011. Epub 2015 Aug 30.


The introduction of highly effective therapies and clearly defined targets has altered the treatment paradigm in psoriatic arthritis (PsA). Validated classification criteria and outcome measures specific to PsA have helped standardize a therapeutic approach to this heterogeneous disease that affects multiple clinical domains. This article discusses the importance of early intervention using a treat-to-target strategy; emerging evidence for tight control based on minimal disease activity criteria; disease considerations specific to PsA (prognostic markers, biomarkers, subclinical disease, comorbidities); and new treatment strategies to deal with refractory disease (eg, tumor necrosis factor inhibitor switching and use of novel disease-modifying therapies) and controlled disease (eg, tapering or discontinuing biologic therapy).

Keywords: Anti-TNF drugs; Comorbidities; DMARDs (biologic); Dose reduction; Minimal disease activity criteria; Psoriatic arthritis; Tight control; Treat-to-target.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Psoriatic / diagnosis*
  • Arthritis, Psoriatic / drug therapy*
  • Biological Therapy / methods*
  • Early Diagnosis*
  • Humans


  • Antirheumatic Agents